
Arvinas, Inc.
NASDAQ:ARVN
9.03 (USD) • At close March 12, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Arvinas, Inc. |
Symbool | ARVN |
Munteenheid | USD |
Prijs | 9.03 |
Beurswaarde | 621,010,257 |
Dividendpercentage | 0% |
52-weken bereik | 7.91 - 46.51 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. John G. Houston Ph.D. |
Website | https://www.arvinas.com |
An error occurred while fetching data.
Over Arvinas, Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)